Phase-IIa randomized, double-blind, sham-controlled, parallel group trial on anodal transcranial direct current stimulation (tDCS) over the left and right tempo-parietal junction in autism spectrum disorder-StimAT: study protocol for a clinical trial.
Autism spectrum disorder
Randomized controlled trial
Tempo-parietal junction
Transcranial direct current stimulation
tDCS
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
06 Apr 2021
06 Apr 2021
Historique:
received:
29
10
2020
accepted:
06
03
2021
entrez:
7
4
2021
pubmed:
8
4
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Autism spectrum disorder (ASD) is characterized by impaired social communication and interaction, and stereotyped, repetitive behaviour and sensory interests. To date, there is no effective medication that can improve social communication and interaction in ASD, and effect sizes of behaviour-based psychotherapy remain in the low to medium range. Consequently, there is a clear need for new treatment options. ASD is associated with altered activation and connectivity patterns in brain areas which process social information. Transcranial direct current stimulation (tDCS) is a technique that applies a weak electrical current to the brain in order to modulate neural excitability and alter connectivity. Combined with specific cognitive tasks, it allows to facilitate and consolidate the respective training effects. Therefore, application of tDCS in brain areas relevant to social cognition in combination with a specific cognitive training is a promising treatment approach for ASD. A phase-IIa pilot randomized, double-blind, sham-controlled, parallel-group clinical study is presented, which aims at investigating if 10 days of 20-min multi-channel tDCS stimulation of the bilateral tempo-parietal junction (TPJ) at 2.0 mA in combination with a computer-based cognitive training on perspective taking, intention and emotion understanding, can improve social cognitive abilities in children and adolescents with ASD. The main objectives are to describe the change in parent-rated social responsiveness from baseline (within 1 week before first stimulation) to post-intervention (within 7 days after last stimulation) and to monitor safety and tolerability of the intervention. Secondary objectives include the evaluation of change in parent-rated social responsiveness at follow-up (4 weeks after end of intervention), change in other ASD core symptoms and psychopathology, social cognitive abilities and neural functioning post-intervention and at follow-up in order to explore underlying neural and cognitive mechanisms. If shown, positive results regarding change in parent-rated social cognition and favourable safety and tolerability of the intervention will confirm tDCS as a promising treatment for ASD core-symptoms. This may be a first step in establishing a new and cost-efficient intervention for individuals with ASD. The trial is registered with the German Clinical Trials Register (DRKS), DRKS00014732 . Registered on 15 August 2018. This study protocol refers to protocol version 1.2 from 24 May 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Autism spectrum disorder (ASD) is characterized by impaired social communication and interaction, and stereotyped, repetitive behaviour and sensory interests. To date, there is no effective medication that can improve social communication and interaction in ASD, and effect sizes of behaviour-based psychotherapy remain in the low to medium range. Consequently, there is a clear need for new treatment options. ASD is associated with altered activation and connectivity patterns in brain areas which process social information. Transcranial direct current stimulation (tDCS) is a technique that applies a weak electrical current to the brain in order to modulate neural excitability and alter connectivity. Combined with specific cognitive tasks, it allows to facilitate and consolidate the respective training effects. Therefore, application of tDCS in brain areas relevant to social cognition in combination with a specific cognitive training is a promising treatment approach for ASD.
METHODS
METHODS
A phase-IIa pilot randomized, double-blind, sham-controlled, parallel-group clinical study is presented, which aims at investigating if 10 days of 20-min multi-channel tDCS stimulation of the bilateral tempo-parietal junction (TPJ) at 2.0 mA in combination with a computer-based cognitive training on perspective taking, intention and emotion understanding, can improve social cognitive abilities in children and adolescents with ASD. The main objectives are to describe the change in parent-rated social responsiveness from baseline (within 1 week before first stimulation) to post-intervention (within 7 days after last stimulation) and to monitor safety and tolerability of the intervention. Secondary objectives include the evaluation of change in parent-rated social responsiveness at follow-up (4 weeks after end of intervention), change in other ASD core symptoms and psychopathology, social cognitive abilities and neural functioning post-intervention and at follow-up in order to explore underlying neural and cognitive mechanisms.
DISCUSSION
CONCLUSIONS
If shown, positive results regarding change in parent-rated social cognition and favourable safety and tolerability of the intervention will confirm tDCS as a promising treatment for ASD core-symptoms. This may be a first step in establishing a new and cost-efficient intervention for individuals with ASD.
TRIAL REGISTRATION
BACKGROUND
The trial is registered with the German Clinical Trials Register (DRKS), DRKS00014732 . Registered on 15 August 2018.
PROTOCOL VERSION
METHODS
This study protocol refers to protocol version 1.2 from 24 May 2019.
Identifiants
pubmed: 33823927
doi: 10.1186/s13063-021-05172-1
pii: 10.1186/s13063-021-05172-1
pmc: PMC8025356
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
248Subventions
Organisme : Horizon 2020
ID : 731827
Références
J Neurosci. 2011 Sep 7;31(36):12849-54
pubmed: 21900563
Appl Psychophysiol Biofeedback. 2010 Jun;35(2):147-61
pubmed: 19941058
J Cogn Neurosci. 2017 Sep;29(9):1498-1508
pubmed: 28253083
J Adolesc Health. 1993 May;14(3):190-5
pubmed: 8323929
Brain Res Bull. 2015 Oct;119(Pt A):25-33
pubmed: 26449209
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
Brain Stimul. 2008 Jul;1(3):151-63
pubmed: 20633382
Neuroimage. 2013 Apr 15;70:48-58
pubmed: 23274187
Front Cell Neurosci. 2016 Mar 22;10:72
pubmed: 27147964
Front Hum Neurosci. 2014 Oct 21;8:851
pubmed: 25374530
Pediatrics. 2014 Mar;133(3):e520-9
pubmed: 24515505
J Autism Dev Disord. 2018 Jul;48(7):2293-2307
pubmed: 29423608
Neuroimage. 2015 Oct 1;119:164-74
pubmed: 26116964
Soc Neurosci. 2015 Aug;10(4):391-407
pubmed: 25666361
Clin Neurophysiol. 2003 Nov;114(11):2220-2; author reply 2222-3
pubmed: 14580622
J Neural Transm (Vienna). 2018 Dec;125(12):1857-1866
pubmed: 30341695
J ECT. 2011 Jun;27(2):134-40
pubmed: 20938352
Brain Stimul. 2016 Sep-Oct;9(5):641-661
pubmed: 27372845
Behav Neurol. 2014;2014:173073
pubmed: 25530675
Expert Rev Pharmacoecon Outcomes Res. 2005 Jun;5(3):353-64
pubmed: 19807604
Clin Linguist Phon. 2011 Jun;25(6-7):640-54
pubmed: 21631313
Dev Neurorehabil. 2018 Apr;21(3):141-154
pubmed: 28394669
J Child Psychol Psychiatry. 2016 May;57(5):596-605
pubmed: 26715086
J Neurother. 2010 Jul 1;14(3):179-194
pubmed: 21116441
Epilepsy Res. 2011 Nov;97(1-2):142-5
pubmed: 21885255
Neuropsychologia. 2006;44(4):610-21
pubmed: 16140346
Neuroimage. 2014 Jan 15;85 Pt 3:1058-68
pubmed: 23880500
Dev Med Child Neurol. 2019 Mar;61(3):298-304
pubmed: 30451290
J Child Psychol Psychiatry. 2005 Dec;46(12):1255-68
pubmed: 16313426
J Autism Dev Disord. 2018 Jan;48(1):198-208
pubmed: 28932960
Brain Stimul. 2011 Oct;4(4):275-80
pubmed: 22032743
Brain Res Bull. 2007 May 30;72(4-6):208-14
pubmed: 17452283
Soc Neurosci. 2019 Dec;14(6):681-696
pubmed: 30668274
Philos Trans R Soc Lond B Biol Sci. 2010 Jan 12;365(1537):165-76
pubmed: 20008394
Front Syst Neurosci. 2014 Aug 06;8:134
pubmed: 25147508
Clin Neurophysiol. 2004 Oct;115(10):2419-23
pubmed: 15351385
Autism Res. 2012 Jun;5(3):160-79
pubmed: 22495912
Behav Sci (Basel). 2017 Sep 17;7(3):
pubmed: 28926975
J Am Acad Child Adolesc Psychiatry. 2017 Jun;56(6):466-474
pubmed: 28545751
Curr Biol. 2012 Dec 4;22(23):2274-7
pubmed: 23122848
Front Hum Neurosci. 2015 Dec 14;9:659
pubmed: 26696868
J Autism Dev Disord. 2010 Dec;40(12):1521-30
pubmed: 20405194
Soc Cogn Affect Neurosci. 2014 Jan;9(1):98-105
pubmed: 22977198
Brain Topogr. 2012 Jul;25(3):332-44
pubmed: 22392009
Clin Neurophysiol. 2017 Sep;128(9):1774-1809
pubmed: 28709880
Eur Child Adolesc Psychiatry. 2006 Aug;15(5):282-91
pubmed: 16554960
Appl Psychophysiol Biofeedback. 2016 Mar;41(1):81-92
pubmed: 26377686
J Child Adolesc Psychopharmacol. 2016 Sep;26(7):590-7
pubmed: 27027666
Behav Neurol. 2015;2015:928631
pubmed: 25861158
Cognition. 2014 Jun;131(3):345-54
pubmed: 24632324
Neuroscientist. 2011 Feb;17(1):37-53
pubmed: 21343407
J Neurodev Disord. 2010 Jun;2(2):62-9
pubmed: 22127855
J Physiol. 2000 Sep 15;527 Pt 3:633-9
pubmed: 10990547
Front Integr Neurosci. 2020 Feb 07;13:71
pubmed: 32116579
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):485-503
pubmed: 22971035
Neurosci Biobehav Rev. 2015 Aug;55:547-72
pubmed: 26073069
Clin Psychol Rev. 2017 Mar;52:164-181
pubmed: 28130983
Brain Stimul. 2016 Jul-Aug;9(4):501-17
pubmed: 27160468
Neurology. 2005 Mar 8;64(5):872-5
pubmed: 15753425
Clin Neurophysiol. 2020 May;131(5):1146-1154
pubmed: 32029377
Neuropsychobiology. 2019;78(4):189-199
pubmed: 31266030
Q J Exp Psychol. 1980 Feb;32(1):3-25
pubmed: 7367577
J Child Psychol Psychiatry. 2017 Sep;58(9):1053-1061
pubmed: 28464350
Schizophr Res. 2013 Mar;144(1-3):153-4
pubmed: 23336963
Front Hum Neurosci. 2016 Jun 06;10:270
pubmed: 27375462
J Autism Dev Disord. 2007 May;37(5):855-66
pubmed: 17048092
Transl Neurosci. 2012 Jun 1;3(2):170-180
pubmed: 24683490
Neurosci Biobehav Rev. 2014 May;42:9-34
pubmed: 24486722
Autism. 2015 Feb;19(2):158-67
pubmed: 24443331
Brain Stimul. 2015 Jan-Feb;8(1):76-87
pubmed: 25499471
Cereb Cortex. 2012 Aug;22(8):1894-903
pubmed: 21955921
Cereb Cortex. 2011 Oct;21(10):2233-43
pubmed: 21378114
Nature. 2000 Jan 20;403(6767):309-12
pubmed: 10659849
J ECT. 2018 Sep;34(3):e25-e35
pubmed: 30095685
Trends Cogn Sci. 2016 Feb;20(2):107-120
pubmed: 26655436
Lancet. 2006 Jul 15;368(9531):210-5
pubmed: 16844490
Mol Autism. 2017 Jul 28;8:40
pubmed: 28775825
PLoS One. 2017 Dec 6;12(12):e0186502
pubmed: 29211740
Acta Psychiatr Scand. 2016 Jun;133(6):445-52
pubmed: 26763353
Front Cell Neurosci. 2015 Aug 11;9:307
pubmed: 26321911
Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2608-20
pubmed: 23999082
Clin Neurophysiol. 2006 Apr;117(4):845-50
pubmed: 16427357
Brain Stimul. 2014 Nov-Dec;7(6):793-9
pubmed: 25153776
Front Neurosci. 2018 Apr 16;12:201
pubmed: 29713261
Neuroimage. 2014 Apr 1;89:216-25
pubmed: 24345389
Front Hum Neurosci. 2018 Apr 13;12:128
pubmed: 29706876
Neuroimage. 2001 Jul;14(1 Pt 1):170-81
pubmed: 11525326
Autism. 2015 Jul;19(5):562-9
pubmed: 24913778